CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia.

When examining the MRD pos subset of patients, we found that compared to patients given high CD34+ doses (MRD pos /high CD34+; n = 52), those who received low CD34+ doses (MRD pos /low CD34+; n = 20) trended toward, but did not reach statistical significance for, a higher risk of relapse (80% [52–93%] vs. 58% [43–70%], p = 0.073).

also in 111,027 other papers

Unlike other studies, we did not find that higher CD34+ doses resulted in a statistically significant increased risk of chronic GVHD in our analyses, although there was a trend toward significance [ 17 , 19 , 20 , 23 ].

also in 3,729 other papers